Limits...
Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

Filippini M, Bazzani C, Atzeni F, Sarzi Puttini P, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R - Biomed Res Int (2014)

Bottom Line: This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA.Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

View Article: PubMed Central - PubMed

Affiliation: Rheumatology and Immunology Unit, Spedali Civili di Brescia, Piazza le Spedali Civili 1, 125123 Brescia, Italy.

ABSTRACT
This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

Show MeSH
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4109221&req=5

Mentions: Two hundred and seventy-five patients (26.62%) switched from the first to a second TNF blocker because of a secondary lack of effectiveness (58.55%), adverse events (30.55%), or other reasons (10.9%): the most frequently discontinued drug was infliximab, which was most frequently replaced by etanercept. The patients who did not need to modify their biological treatment had less residual disability than those who had to switch (HAQ 0.6 versus 0.89; P < 0.05) (Figure 2), but the improvement in HAQ scores was significant after five years of followup in both subgroups (ΔHAQ > MID; P < 0.05).


Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.

Filippini M, Bazzani C, Atzeni F, Sarzi Puttini P, Marchesoni A, Favalli EG, Caporali R, Cavagna L, Gorla R - Biomed Res Int (2014)

© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4109221&req=5

Mentions: Two hundred and seventy-five patients (26.62%) switched from the first to a second TNF blocker because of a secondary lack of effectiveness (58.55%), adverse events (30.55%), or other reasons (10.9%): the most frequently discontinued drug was infliximab, which was most frequently replaced by etanercept. The patients who did not need to modify their biological treatment had less residual disability than those who had to switch (HAQ 0.6 versus 0.89; P < 0.05) (Figure 2), but the improvement in HAQ scores was significant after five years of followup in both subgroups (ΔHAQ > MID; P < 0.05).

Bottom Line: This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA.Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

View Article: PubMed Central - PubMed

Affiliation: Rheumatology and Immunology Unit, Spedali Civili di Brescia, Piazza le Spedali Civili 1, 125123 Brescia, Italy.

ABSTRACT
This study involving 1033 patients with RA confirms the effectiveness of etanercept, adalimumab, and infliximab in reducing RA-related disability even in patients with a history of highly active and longstanding RA. Moreover, we found that the improvement in disability was biphasic, with a marked improvement during the first year of anti-TNF therapy, followed by slower but significant recovery over the subsequent four years.

Show MeSH